The mechanism of action (MOA) for their inhibition of SOS1 are identical, which could be explained by disrupting the RAS binding epitope on SOS1 interaction sterically.396,398 BAY-293 was reported to show anti-proliferative activity in both KRAS mutant and wild-type human cancer cell lines, and the efficacy of this could be enhanced by the combination of ARS-853, a covalent inhibitor of KRASG12C 396. Here, KRAS is linked to cancer.